



ORAL PRESENTATION

Open Access

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Georgina V Long¹, Victoria Atkinson², Paolo A Ascierto^{3*}, Benjamin Brady⁴, Caroline Dutriaux⁵, Michele Maio⁶, Laurent Mortier⁷, Jessica C. Hassel⁸, Piotr Rutkowski⁹, Catriona McNeil¹⁰, Ewa Kalinka-Warzocho¹¹, Kerry J. Savage¹², Micaela Hernberg¹³, Celeste Lebbé¹⁴, Julie Charles¹⁵, Catalin Mihalciou¹⁶, Vanna Chiarion-Sileni¹⁷, Cornelia Mauch¹⁸, Henrik Schmidt¹⁹, Dirk Schadendorf²⁰, Helen Gogas²¹, Christine Horak²², Brian Sharkey²³, Ian M. Waxman²², Caroline Robert²⁴

From Melanoma Bridge Meeting 2014
Naples, Italy. 03-06 December 2014

Background

The phase 1 study of nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody, showed promising antitumor activity in patients with advanced melanoma.

Materials and methods

This phase 3 study compared nivolumab vs dacarbazine in treatment-naïve patients with BRAF wild-type metastatic melanoma. Patients were randomized 1:1 to receive nivolumab 3 mg/kg every 2 weeks (Q2W) + placebo Q3W (n = 210) or dacarbazine 1000 mg/m² Q3W + placebo Q2W (n = 208) until disease progression or unacceptable toxicity. Randomization was stratified by M-stage and programmed death ligand-1 (PD-L1) status. The primary endpoint was overall survival (OS). Patients were followed for up to 16.7 months at the time of data cutoff, which occurred 5.2 months after the first visit of the last patient randomized.

Results

The hazard ratio (HR) for death was 0.42 (99.79% CI 0.25–0.73; *P* < 0.0001) in favor of nivolumab, with 1-year OS rate 73% (95% CI, 66%–79%) for nivolumab vs 42% (95% CI, 33%–51%) for dacarbazine. Median OS was not reached for nivolumab and was 10.8 months for dacarbazine. Median progression-free survival (PFS) was 5.1 months for nivolumab and 2.2 months for dacarbazine (HR for death or progression 0.43, 95% CI 0.34–0.56; *P* < 0.0001). Objective response rate was

40% (84/210) vs 14% (29/208) for nivolumab and dacarbazine, respectively (*P* < 0.0001). Median duration of response was not reached for nivolumab and 6 months for dacarbazine. At the time of data cutoff, responses were ongoing in 86% (72/84) of nivolumab and 52% (15/29) of dacarbazine responders. PD-L1 positivity (using a 5% tumor cell surface staining cutoff) appeared to be associated with improved OS in the nivolumab arm (85% of PD-L1+ and 71% of PD-L1-/indeterminate patients alive at the time of last follow-up). Both PD-L1+ and PD-L1-/indeterminate patients receiving nivolumab had improved OS vs dacarbazine (un-stratified HR 0.30, 95% CI, 0.15–0.60 in PD-L1+ patients; 0.48, 95% CI, 0.32–0.71 in PD-L1-/indeterminate patient, both in favor of the nivolumab arm). The most common nivolumab-related adverse events (AEs) were fatigue, pruritus, and nausea. Drug-related grade 3–4 AEs were reported in 12% vs 18% of patients receiving nivolumab vs dacarbazine, respectively. AEs led to discontinuation in 7% and 12% of dacarbazine- vs nivolumab-treatment patients, respectively.

Conclusions

Compared to dacarbazine, nivolumab significantly improved OS and PFS in previously untreated patients with BRAF wild-type metastatic melanoma with an acceptable safety profile.

Clinical Trial Registration Number

NCT01721772.

³Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
Full list of author information is available at the end of the article

Authors' details

¹Melanoma Institute Australia, University of Sydney, and Mater Hospital, Sydney, Australia. ²Princess Alexandra Hospital, Woolloongabba & Gallipoli Medical Research Foundation, Greenslopes Private Hospital Queensland, Australia. ³Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. ⁴Cabrini Health, Melbourne, Australia. ⁵Hôpital Saint André CHU, Bordeaux, France. ⁶University Hospital of Siena, Siena, Italy. ⁷Hôpital Claude Huriez, Lille, France. ⁸University Hospital Heidelberg & National Center for Tumor Diseases, Heidelberg, Germany. ⁹Maria Skłodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland. ¹⁰Chris O'Brien Lifehouse, The Melanoma Institute Australia & Royal Prince Alfred Hospital, Camperdown, Australia. ¹¹Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland. ¹²British Columbia Cancer Agency, Vancouver, Canada, Canada. ¹³Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. ¹⁴APHP Dermatology and CIC Hôpital Saint Louis Paris 7 University, INSERM 976, Paris, France. ¹⁵Grenoble University Hospital Grenoble France - INSERM U823, Joseph Fourier University, Grenoble, France. ¹⁶Royal Victoria Hospital, Alberta, Canada. ¹⁷Oncology Institute of Veneto IRCCS, Padua, Italy. ¹⁸Department of Dermatology, University Hospital Cologne and CIO Köln Bonn, Germany. ¹⁹Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. ²⁰Department of Dermatology, University of Essen, Essen, Germany. ²¹University of Athens Medical School, Laiko General Hospital, Athens, Greece. ²²Bristol-Myers Squibb, Lawrenceville, NJ, USA. ²³Bristol-Myers Squibb, Wallingford, CT, USA. ²⁴Gustave, Roussy and INSERM U981, Villejuif-Paris-Sud, France.

Published: 15 January 2015

doi:10.1186/1479-5876-13-S1-O6

Cite this article as: Long *et al.*: Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. *Journal of Translational Medicine* 2015 **13**(Suppl 1):O6.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

